The Editors and Editorial board have developed the “Rules of 3”. Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work. The rules are also used as guidelines for the peer review of manuscripts.

1. **Out of scope**
The paper must report on recent advances in pharmaceutical technology, biopharmaceutics and pharmaceutical biotechnology of major importance

*Immediate rejection criteria:*
I. Description of analytical methods with no relation to pharmaceutics, biopharmaceutics or pharmaceutical biotechnology
II. Mere description of compound synthesis, processes, validation, etc. without any pharmaceutical application
III. Inappropriate promotion of a trademark or a product
IV. Regulatory issues with no relation to pharmaceutics, biopharmaceutics or pharmaceutical biotechnology

2. **Too preliminary**
A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented.

*Immediate rejection criteria:*
I. No proof of concept in either an in vivo or an in vitro evaluation
II. No clear indication of the use of the product or formulation
III. No clear description of the materials & methods used in the pharmaceutical field
IV. Use of inadequate or insufficient methods
V. Inappropriate statistical analysis
VI. Lack of proper controls
VII. Lack of coherent discussion of the results

3. **Lack of novelty**
The study described in the manuscript must represent a novel approach

*Immediate rejection criteria:*
I. Repetition of previously published data, either partially or entirely
II. Simple variation of parameters of a formulation, processes, synthesis, etc.
III. Modification of well-known delivery systems with no novelty and/or benefit